会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • NON-STERILE FERMENTATION OF BIOETHANOL
    • 生物柴油的非纯化发酵
    • WO2009090480A3
    • 2009-09-03
    • PCT/IB2008003536
    • 2008-12-18
    • INBICON ASLARSEN JAN
    • LARSEN JAN
    • C12P7/06C12P7/10
    • C12P7/06A01N43/08A01N61/00A01N65/00A01N65/44C12N1/22C12P7/10C12P2201/00Y02E50/16Y02E50/17
    • A range of concentrations exists in which fermentation inhibitors derived from pretreatment of lignocellulosic feed stocks inhibit growth of lactic acid bacteria without affecting fermentive yeast. By optimizing levels of fermentation inhibitors to fall within this range, yeast fermentations of lignocellulosic biomass can be conducted under non-sterile conditions with ethanol yields comparable to those achieved under sterile conditions. Optimised inhibitor levels can be achieved by controlling the water/biomass ratio of a lignocellulosic biomass during and after pretreatment, for example by washing the fiber fraction of a previously pretreated lignocellulosic biomass with a pre-defined amount of fresh water or recycled process solutions. Crude extracts of liquid fraction or process solutions from pretreatment of lignocellulosic biomass can also provide an effective anti-baterial treatment for first generation starch fermentations.
    • 存在一定范围的浓度,其中衍生自木质纤维素原料的预处理的发酵抑制剂抑制乳酸菌的生长而不影响发酵酵母。 通过优化发酵抑制剂的含量落在此范围内,木质纤维素生物质的酵母发酵可以在非无菌条件下进行,乙醇产量与在无菌条件下达到的相似。 优化的抑制剂水平可以通过在预处理期间和之后控制木质纤维素生物质的水/生物量比来实现,例如通过用预定量的淡水或再循环的处理溶液洗涤先前预处理的木质纤维素生物质的纤维部分。 来自木质纤维素生物质预处理的液体馏分或处理溶液的粗提取物也可为第一代淀粉发酵提供有效的抗物质处理。
    • 6. 发明申请
    • NON-STERILE FERMENTATION OF BIOETHANOL
    • 生物乙醇的非无菌发酵
    • WO2009090480A4
    • 2009-11-12
    • PCT/IB2008003536
    • 2008-12-18
    • INBICON ASLARSEN JAN
    • LARSEN JAN
    • C12P7/06C12P7/10
    • C12P7/06A01N43/08A01N61/00A01N65/00A01N65/44C12N1/22C12P7/10C12P2201/00Y02E50/16Y02E50/17
    • A range of concentrations exists in which fermentation inhibitors derived from pretreatment of lignocellulosic feed stocks inhibit growth of lactic acid bacteria without affecting fermentive yeast. By optimizing levels of fermentation inhibitors to fall within this range, yeast fermentations of lignocellulosic biomass can be conducted under non-sterile conditions with ethanol yields comparable to those achieved under sterile conditions. Optimised inhibitor levels can be achieved by controlling the water/biomass ratio of a lignocellulosic biomass during and after pretreatment, for example by washing the fiber fraction of a previously pretreated lignocellulosic biomass with a pre-defined amount of fresh water or recycled process solutions. Crude extracts of liquid fraction or process solutions from pretreatment of lignocellulosic biomass can also provide an effective anti-baterial treatment for first generation starch fermentations.
    • 存在一系列浓度,其中源自木质纤维素原料的预处理的发酵抑制剂抑制乳酸菌的生长而不影响发酵性酵母。 通过优化发酵抑制剂的水平以使其落入该范围内,木质纤维素生物质的酵母发酵可以在非无菌条件下进行,其中乙醇产率与无菌条件下获得的乙醇产量相当。 通过在预处理期间和之后控制木质纤维素生物质的水/生物质比率,例如通过用预定量的淡水或回收的工艺溶液洗涤先前预处理的木质纤维素生物质的纤维部分,可以实现优化的抑制剂水平。 来自木质纤维素生物质预处理的液体馏分或工艺溶液的粗提物也可为第一代淀粉发酵提供有效的抗菌处理。
    • 10. 发明申请
    • QUALITY AND SAFETY ASSURANCE OF MEDICAL APPLICATIONS
    • 医疗应用的质量和安全保证
    • WO0195253A3
    • 2002-05-10
    • PCT/DK0100396
    • 2001-06-08
    • MEDIMAGE APSNIELSEN PETER MICHAELLARSEN JAN
    • NIELSEN PETER MICHAELLARSEN JAN
    • G06N3/02
    • G06N3/02
    • The present invention relates in a broad aspect to assurance of quality and safety of medical applications determining - or suggesting - diagnosis and/or treatment. In general, such applications are according to the present invention applications which are designed to operate without assistance of a medical adviser in daily use and accordingly these applications must be supervised in some sense in order to be able to guarantee that diagnoses and/or treatments determined by these applications are not determined in a manner that patients are exposed to life threatening treatment due to malfunctioning of these applications. In the general perspective according to the present invention, treatment is suggested based on a diagnosis and a diagnosis is viewed upon as recognition of a pattern. For instance, a diagnosis is the result of recognition of a pattern of antibody substances in a sample taken from the tissue of a patient. Furthermore, the term diagnosis has been given a broad interpretation in the present content so as to include - and/or even be- determination of treatment. The philosophy behind such an approach is that the determination of a treatment is according to the present invention based on determination of a pattern. For instance in case of the prescription of a drug preventing attacks of Multiple Sclerosis, a measured blood sample may be analyzed for patterns of matter in the sample and once a pattern is recognized the treatment assigned to said pattern is the treatment suggested.
    • 本发明在广泛的方面涉及确定或建议诊断和/或治疗的医疗应用的质量和安全性的保证。 一般来说,这样的应用是根据本发明的应用程序,其被设计为在日常使用中没有医疗顾问的协助下运行,因此这些应用程序必须在某种意义上被监督,以便能够保证诊断和/或治疗确定 通过这些应用不能以由于这些应用的故障使患者面临威胁生命的治疗的方式来确定。 在根据本发明的一般观点中,基于诊断提出治疗,并且将诊断视为模式的识别。 例如,诊断是识别从患者组织中取出的样品中的抗体物质的模式的结果。 此外,术语诊断已经在本内容中被广泛解释,以包括 - 和/或甚至是确定治疗。 这种方法背后的理念是,基于确定模式,根据本发明确定治疗。 例如,在处方药物预防多发性硬化症发作的情况下,可以分析测量的血液样品中的样品中的物质模式,并且一旦识别出模式,则分配给所述模式的治疗是所建议的治疗方法。